Setting

North America Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247662 | Pages: 139

North America digital biomarkers market is expected to grow by 35.8% annually in the forecast period and reach $6,747.2 million by 2030 driven by rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic. Highlighted with 32 tables and 63 figures, this 139-page report “North America Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country. Based on System Component, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Data Collection Tools • Digital Platforms • Mobile Apps • Desktop-based Software • Wearables • Biosensors Data Integration Systems Based on Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cardiovascular Diseases Neurodegenerative Disorders • Parkinson’s Disease • Multiple Sclerosis • Alzheimer’s Disease Sleep and Movement Diseases Psychiatric Disorders Chronic Pain Gastrointestinal Diseases Diabetes Respiratory Conditions Other Diseases Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Wellness • Disease Diagnosis • Personalised Medication • Drug Discovery and Development Based on Development Status, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Novel Digital Biomarkers • Original Digital Biomarkers • Approved Digital Biomarkers Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Biopharmaceutical Companies & Labs • Healthcare Providers • Insurance Payers Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Actigraph LLC Akili Interactive Labs AliveCor Inc Altoida Inc Amgen Inc Bayer AG Biogen Inc Cambridge Cognition Plc Eli Lilly and Company Evidation Health, Inc. F. Hoffmann-La Roche Ltd Fitbit Inc GlaxoSmithKline Plc Happify Health Human API IXICO Plc Koninklijke Philips N.V. Medical Care Corporation Medopad Ltd Mindstrong Health Neurotrack Technology, Inc Novartis International AG Pfizer Inc. Quanterix Corporation Sanofi S.A. The Takeda Pharmaceuticals Company Limited Verily Life Sciences Winterlight Labs Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on the Market	25
2.2 Major Growth Drivers	27
2.3 Market Restraints and Challenges	32
2.4 Emerging Opportunities and Market Trends	37
2.5 Porter’s Fiver Forces Analysis	41
3 Segmentation of North America Market by System Component	45
3.1 Market Overview by System Component	45
3.2 Data Collection Tools	47
3.2.1 Digital Platforms	49
3.2.2 Mobile Apps	50
3.2.3 Desktop-based Software	51
3.2.4 Wearables	52
3.2.5 Biosensors	53
3.3 Data Integration Systems	54
4 Segmentation of North America Market by Therapeutic Area	55
4.1 Market Overview by Therapeutic Area	55
4.2 Cardiovascular Diseases	57
4.3 Neurodegenerative Disorders	58
4.3.1 Parkinson’s Disease	60
4.3.2 Multiple Sclerosis	61
4.3.3 Alzheimer’s Disease	62
4.4 Sleep and Movement Diseases	63
4.5 Psychiatric Disorders	64
4.6 Chronic Pain	65
4.7 Gastrointestinal Diseases	66
4.8 Diabetes	67
4.9 Respiratory Conditions	68
4.10 Other Diseases	69
5 Segmentation of North America Market by Application	70
5.1 Market Overview by Application	70
5.2 Wellness	72
5.3 Disease Diagnosis	73
5.4 Personalised Medication	74
5.5 Drug Discovery and Development	75
6 Segmentation of North America Market by Development Status	77
6.1 Market Overview by Development Status	77
6.2 Novel Digital Biomarkers	80
6.3 Original Digital Biomarkers	81
6.4 Approved Digital Biomarkers	82
7 Segmentation of North America Market by End User	83
7.1 Market Overview by End User	83
7.2 Biopharmaceutical Companies & Labs	85
7.3 Healthcare Providers	86
7.4 Insurance Payers	87
8 North America Market 2019-2030 by Country	88
8.1 Overview of North America Market	88
8.2 U.S.	91
8.3 Canada	95
8.4 Mexico	97
9 Competitive Landscape	99
9.1 Overview of Key Vendors	99
9.2 New Product Launch, Partnership, Investment, and M&A	103
9.3 Company Profiles	104
Actigraph LLC	104
Akili Interactive Labs	106
AliveCor Inc	107
Altoida Inc	108
Amgen Inc	109
Bayer AG	110
Biogen Inc	111
Cambridge Cognition Plc	112
Eli Lilly and Company	113
Evidation Health, Inc.	114
F. Hoffmann-La Roche Ltd	115
Fitbit Inc	116
GlaxoSmithKline Plc	117
Happify Health	118
Human API	119
IXICO Plc	120
Koninklijke Philips N.V.	121
Medical Care Corporation	122
Medopad Ltd	123
Mindstrong Health	124
Neurotrack Technology, Inc	125
Novartis International AG	126
Pfizer Inc.	127
Quanterix Corporation	128
Sanofi S.A.	129
The Takeda Pharmaceuticals Company Limited	130
Verily Life Sciences	131
Winterlight Labs Inc.	132
10 Investing in North America Market: Risk Assessment and Management	133
10.1 Risk Evaluation of North America Market	133
10.2 Critical Success Factors (CSFs)	136
Related Reports and Products	139
List Of Tables

Table 1.  Snapshot of North America Digital Biomarkers Market, 2019-2030	18
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples	22
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030	30
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year	31
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year	31
Table 6. Current Challenges of Digital Biomarkers in Medical Settings	34
Table 7.  Main Product Trends and Market Opportunities in North America Digital Biomarkers Market	37
Table 8. North America Digital Biomarkers Market by System Component, 2019-2030, $ mn	45
Table 9. North America Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn	48
Table 10. North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn	55
Table 11. North America Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn	59
Table 12. North America Digital Biomarkers Market by Application, 2019-2030, $ mn	70
Table 13. North America Digital Biomarkers Market by Development Status, 2019-2030, $ mn	78
Table 14. North America Digital Biomarkers Market by End User, 2019-2030, $ mn	83
Table 15. North America Digital Biomarkers Market by Country, 2019-2030, $ mn	89
Table 16. U.S. Digital Biomarkers Market by System Component, 2019-2030, $ mn	93
Table 17. U.S. Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn	93
Table 18. U.S. Digital Biomarkers Market by End User, 2019-2030, $ mn	93
Table 19. Canada Digital Biomarkers Market by System Component, 2019-2030, $ mn	96
Table 20. Canada Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn	96
Table 21. Canada Digital Biomarkers Market by End User, 2019-2030, $ mn	96
Table 22. Mexico Digital Biomarkers Market by System Component, 2019-2030, $ mn	98
Table 23. Mexico Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn	98
Table 24. Mexico Digital Biomarkers Market by End User, 2019-2030, $ mn	98
Table 25. Breakdown of North America Market by Key Vendor, 2019, %	101
Table 26. Actigraph LLC: Company Snapshot	104
Table 27. Actigraph LLC: Business Segmentation	104
Table 28. Actigraph LLC: Product Portfolio	105
Table 29. Actigraph LLC: Revenue, 2016-2018, $ mn	105
Table 30. Actigraph LLC: Recent Developments	105
Table 31.  Risk Evaluation for Investing in North America Market, 2019-2030	134
Table 32. Critical Success Factors and Key Takeaways	137
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. North America Digital Biomarkers Market, 2019-2030, $ mn	20
Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers	21
Figure 7. Benefits and Challenges of Digital Biomarkers	23
Figure 8. North America Biomarkers Market, 2019-2030, $ mn	24
Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030	24
Figure 10. Impact of COVID-19 on Business	25
Figure 11. Primary Drivers and Impact Factors of North America Digital Biomarkers Market	27
Figure 12. World 5G Traffic, 2019-2030, EB/year	30
Figure 13. Primary Restraints and Impact Factors of North America Digital Biomarkers Market	32
Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers	35
Figure 15. Pathway to Regulatory Approval of Digital Biomarkers	36
Figure 16. Investment Opportunity Analysis	38
Figure 17. Porter’s Fiver Forces Analysis of North America Digital Biomarkers Market	41
Figure 18. Breakdown of North America Digital Biomarkers Market by System Component, 2019-2030, % of Revenue	46
Figure 19. North America Addressable Market Cap in 2020-2030 by System Component, Value ($ mn) and Share (%)	46
Figure 20. North America Digital Biomarkers Market: Data Collection Tools, 2019-2030, $ mn	47
Figure 21. North America Digital Biomarkers Market: Digital Platforms, 2019-2030, $ mn	49
Figure 22. North America Digital Biomarkers Market: Mobile Apps, 2019-2030, $ mn	50
Figure 23. North America Digital Biomarkers Market: Desktop-based Software, 2019-2030, $ mn	51
Figure 24. North America Digital Biomarkers Market: Wearables, 2019-2030, $ mn	52
Figure 25. North America Digital Biomarkers Market: Biosensors, 2019-2030, $ mn	53
Figure 26. North America Digital Biomarkers Market: Data Integration Systems, 2019-2030, $ mn	54
Figure 27. Breakdown of North America Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue	56
Figure 28. North America Addressable Market Cap in 2020-2030 by Therapeutic Area, Value ($ mn) and Share (%)	56
Figure 29. North America Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, $ mn	57
Figure 30. North America Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, $ mn	58
Figure 31. North America Digital Biomarkers Market: Parkinson’s Disease, 2019-2030, $ mn	60
Figure 32. North America Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, $ mn	61
Figure 33. North America Digital Biomarkers Market: Alzheimer’s Disease, 2019-2030, $ mn	62
Figure 34. North America Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, $ mn	63
Figure 35. North America Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, $ mn	64
Figure 36. North America Digital Biomarkers Market: Chronic Pain, 2019-2030, $ mn	65
Figure 37. North America Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, $ mn	66
Figure 38. North America Digital Biomarkers Market: Diabetes, 2019-2030, $ mn	67
Figure 39. North America Digital Biomarkers Market: Respiratory Conditions, 2019-2030, $ mn	68
Figure 40. North America Digital Biomarkers Market: Other Diseases, 2019-2030, $ mn	69
Figure 41. Breakdown of North America Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue	71
Figure 42. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)	71
Figure 43. North America Digital Biomarkers Market: Wellness, 2019-2030, $ mn	72
Figure 44. North America Digital Biomarkers Market: Disease Diagnosis, 2019-2030, $ mn	73
Figure 45. North America Digital Biomarkers Market: Personalised Medication, 2019-2030, $ mn	74
Figure 46. North America Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, $ mn	75
Figure 47. Classification of Digital Biomarkers by Development Status	77
Figure 48. Breakdown of North America Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue	79
Figure 49. North America Addressable Market Cap in 2020-2030 by Development Status, Value ($ mn) and Share (%)	79
Figure 50. North America Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, $ mn	80
Figure 51. North America Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, $ mn	81
Figure 52. North America Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, $ mn	82
Figure 53. Breakdown of North America Digital Biomarkers Market by End User, 2019-2030, % of Revenue	84
Figure 54. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)	84
Figure 55. North America Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, $ mn	85
Figure 56. North America Digital Biomarkers Market: Healthcare Providers, 2019-2030, $ mn	86
Figure 57. North America Digital Biomarkers Market: Insurance Payers, 2019-2030, $ mn	87
Figure 58. Breakdown of North America Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue	89
Figure 59. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)	90
Figure 60. U.S. Digital Biomarkers Market, 2019-2030, $ mn	92
Figure 61. Canada Digital Biomarkers Market, 2019-2030, $ mn	95
Figure 62.  Digital Biomarkers Market in Mexico, 2015-2030, $ mn	97
Figure 63. Growth Stage of North America Digital Biomarkers Industry over the Forecast Period	99




Key Players (this may not be a complete list and extra companies can be added upon request): 
Actigraph LLC	
Akili Interactive Labs	
AliveCor Inc	
Altoida Inc	
Amgen Inc	
Bayer AG	
Biogen Inc	
Cambridge Cognition Plc	
Eli Lilly and Company	
Evidation Health, Inc.	
F. Hoffmann-La Roche Ltd	
Fitbit Inc	
GlaxoSmithKline Plc	
Happify Health	
Human API	
IXICO Plc	
Koninklijke Philips N.V.	
Medical Care Corporation	
Medopad Ltd	
Mindstrong Health	
Neurotrack Technology, Inc	
Novartis International AG	
Pfizer Inc.	
Quanterix Corporation	
Sanofi S.A.	
The Takeda Pharmaceuticals Company Limited	
Verily Life Sciences	
Winterlight Labs Inc.